The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation
Open accessAbstract
The emerging potential for the cannabinoid (CB) system in modulating gastrointestinal inflammation has gained momentum over the last few years. Traditional and anecdotal use of marijuana for gastrointestinal disorders, such as diarrhoea and abdominal cramps is recognized, but the therapeutic benefit of cannabinoids in the 21st century is overshadowed by the psychoactive problems associated with CB 1 receptor activation. However, the presence and function of the CB 2 receptor in the GI tract, whilst not yet well characterized, holds great promise due to its immunomodulatory roles in inflammatory systems and its lack of psychotropic effects. This review of our current knowledge of CB 2 receptors in the gastrointestinal tract highlights its role in regulating abnormal motility, modulating intestinal inflammation and limiting visceral sensitivity and pain. CB 2 receptors represent a braking system and a pathophysiological mechanism for the resolution of inflammation and many of its symptoms. CB 2 receptor activation therefore represents a very promising therapeutic target in gastrointestinal inflammatory states where there is immune activation and motility dysfunction. British Journal of Pharmacology (2008) 153, 263–270; doi:10.1038/sj.bjp.0707486; published online 1 October 2007
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammatory bowel disease: cause and immunobiology
Baumgart, D. C., & Carding, S. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60750-8 · Cited by 2,147
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957
Identification and Functional Characterization of Brainstem Cannabinoid CB2Receptors
Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., et al. (2005) · Science · doi:10.1126/science.1115740 · Cited by 1,470
Self-citationItzkowitz, S. H., & Yio, X. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00079.2004 · Cited by 1,274
The endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090
Inflammation, a Key Event in Cancer Development
Lu, H., Ouyang, W., & Huang, C. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0261 · Cited by 1,028
Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors
Rousseaux, C., Thuru, X., Gelot, A., Barnich, N., Neut, C., Dubuquoy, L., Dubuquoy, C., Merour, E., Geboes, K., Chamaillard, M., et al. (2007) · Nature Medicine · doi:10.1038/nm1521 · Cited by 793 · cited 2×
“Recently, it was shown that the probiotic agent Lactobacillus acidophilus, increased CB2 receptors in the epithelium of treated animals (rats and mice; Rousseaux et al., 2007).”
BackgroundCannabinoid-based drugs as anti-inflammatory therapeutics
Klein, T. W. (2005) · Nature Reviews Immunology · doi:10.1038/nri1602 · Cited by 728
HU-308: A specific agonist for CB 2 , a peripheral cannabinoid receptor
Hanuš, L., Breuer, A., Tchilibon, S., Shiloah, S., Goldenberg, D., Horowitz, M., Pertwee, R. G., Ross, R. A., Mechoulam, R., & Fride, E. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.25.14228 · Cited by 571
Antifibrogenic role of the cannabinoid receptor CB2 in the liver
Julien, B., Grenard, P., Teixeira-Clerc, F., Van Nhieu, J. T., Li, L., Karsak, M., Zimmer, A., Mallat, A., & Lotersztajn, S. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.12.050 · Cited by 470
Cited by
Emerging strategies for exploiting cannabinoid receptor agonists as medicines
Pertwee, R. G. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00048.x · Cited by 436
Cannabinoids and the gut: New developments and emerging concepts
Izzo, A. A., & Sharkey, K. A. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.12.005 · Cited by 419
Self-citationIs lipid signaling through cannabinoid 2 receptors part of a protective system?
Pacher, P., & Mechoulam, R. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2011.01.001 · Cited by 414
Modulating the endocannabinoid system in human health and disease – successes and failures
Pacher, P., & Kunos, G. (2013) · The FEBS Journal · doi:10.1111/febs.12260 · Cited by 405
Early phytocannabinoid chemistry to endocannabinoids and beyond
Mechoulam, R., Hanuš, L. O., Pertwee, R., & Howlett, A. C. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3811 · Cited by 393
Pertwee, R. G. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0381 · Cited by 347
Targeting proteinase-activated receptors: therapeutic potential and challenges
Ramachandran, R., Noorbakhsh, F., DeFea, K., & Hollenberg, M. D. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3615 · Cited by 312
Lipid G Protein-coupled Receptor Ligand Identification Using β-Arrestin PathHunter™ Assay
Yin, H., Chu, A., Li, W., Wang, B., Shelton, F., Otero, F., Nguyen, D. G., Caldwell, J. S., & Chen, Y. A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m806516200 · Cited by 311
The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases
Lowe, H., Toyang, N., Steele, B., Bryant, J., & Ngwa, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179472 · Cited by 303
Cannabinoid Hyperemesis Syndrome
A. Galli, J., Andari Sawaya, R., & K. Friedenberg, F. (2011) · Current Drug Abuse Reviewse · doi:10.2174/1874473711104040241 · Cited by 303
Kang, C., Wang, B., Kaliannan, K., Wang, X., Lang, H., Hui, S., Huang, L., Zhang, Y., Zhou, M., Chen, M., et al. (2017) · mBio · doi:10.1128/mbio.00470-17 · Cited by 272
Bíró, T., Tóth, B. I., Haskó, G., Paus, R., & Pacher, P. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.05.004 · Cited by 271
CB2 Cannabinoid Receptors as a Therapeutic Target—What Does the Future Hold?
Dhopeshwarkar, A., & Mackie, K. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.094649 · Cited by 257
The Role of the Endocannabinoid System in the Brain–Gut Axis
Sharkey, K. A., & Wiley, J. W. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.04.015 · Cited by 253
Self-citationAguilera, M., Cerdà-Cuéllar, M., & Martínez, V (2015) · Gut Microbes · doi:10.4161/19490976.2014.990790 · Cited by 162
Dobrosi, N., Tóth, B. I., Nagy, G., Dózsa, A., Géczy, T., Nagy, L., Zouboulis, C. C., Paus, R., Kovács, L., & Bíró, T. (2008) · The FASEB Journal · doi:10.1096/fj.07-104877 · Cited by 142
Brusberg, M., Arvidsson, S., Kang, D., Larsson, H., Lindström, E., & Martinez, V. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5166-08.2009 · Cited by 88
Aggarwal, S. K. (2013) · The Clinical Journal of Pain · doi:10.1097/ajp.0b013e31824c5e4c · Cited by 62
Metadata
- Authors
- Wright, K. L., Duncan, M., & Sharkey, K. A.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2008-01
- Volume
- 153
- Issue
- 2
- Pages
- 263-270
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1964856587
- Cited by
- 264
- References
- 59
- FWCI
- 9.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.